This study aims to evaluate the clinical application values of Remote Monitoring (RM) in postpacemaker implantation follow-up. A total of 105 patients implanted with Dual-Chamber Pacemaker (DCPM) in our hospital were divided into the HM group (n=59, implanted the HM system, Biotronik, German) and the control group (group N, n=46). The Average Outpatient Follow-Up Times (AOFT), alarm events, all-cause mortality, stroke rate, cardiogenic readmission rate, arrhythmia, and heart functions between the two groups within 12 mon after the implantation were then compared. The followup lasted 359.21 ± 17.23 d, and 26452 pieces of data were accumulatively obtained by the HM system network center, including daily data alarm events (n=813), among which "Missing messages>7 d" accounted for 37.98%, and "mode switching" accounted for 20.83%. Compared with group N, AOFT of each patient in group RM was significantly less (P<0.01); the patients with new-onset stroke or readmitted were less (P<0.05); the patients with new-onset atrial fibrillation were more (P<0.05); the patients with NYHA III were less (P<0.05), but the mortality, patients with new-onset atrial tachycardia, ventricular tachycardia, or ventricular fibrillation, and LVEF showed no significant difference. RM could be safely and effectively applied in following up the DCPM patients, and could effectively reduce the outpatient follow-up times, detect asymptomatic arrhythmic events, effectively reduce the occurrence of cardio-cerebrovascular events through timely intervention, and improve heart functions and readmission risk.